Koers Evogene Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
EVGN
IL0011050551
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 17 mln. 64,33 mln. 15,88 mln. | Omzet 2025 * | 31,5 mln. 119 mln. 29,42 mln. | Marktkapitalisatie | 34,7 mln. 131 mln. 32,41 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -20 mln. -75,68 mln. -18,68 mln. | Nettowinst (verlies) 2025 * | -17 mln. -64,33 mln. -15,88 mln. | EV/omzet 2024 * | 2,04 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,1 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,34% |
Recentste transcriptie over Evogene Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-01-02 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 01-04-22 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 01-01-05 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 17-11-21 |
Sarit Firon
CHM | Chairman | 58 | 11-08-16 |
Leon Recanati
BRD | Director/Board Member | 76 | 01-05-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,09% | 43,43 mld. | |
+47,81% | 41,69 mld. | |
+9,45% | 41,31 mld. | |
-10,92% | 27,14 mld. | |
+9,32% | 25,28 mld. | |
-24,87% | 18,47 mld. | |
+29,70% | 12,59 mld. | |
+1,28% | 12,33 mld. | |
+7,78% | 11,03 mld. |